Similar articles

• [Neoadjuvant treatment of operable esophageal cancers].

  Azria D, Ychou M, Senesse P, Dubois JB. Azria D, et al. Gastroenterol Clin Biol. 1999 Oct;23(10):1107-8. Gastroenterol Clin Biol. 1999. PMID: 10592891 Clinical Trial. French. No abstract available.
• Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.

  Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA. Heath EI, et al. J Clin Oncol. 2000 Feb;18(4):868-76. doi: 10.1200/JCO.2000.18.4.868. J Clin Oncol. 2000. PMID: 10673530 Clinical Trial.
• [No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].

  Fietkau R. Fietkau R. Strahlenther Onkol. 1999 May;175(5):251-2. doi: 10.1007/BF02742406. Strahlenther Onkol. 1999. PMID: 10356618 Clinical Trial. German. No abstract available.
• Neoadjuvant treatment of oesophageal adenocarcinoma.

  Robb WB, Naughton P, Walsh TN. Robb WB, et al. Minerva Chir. 2004 Oct;59(5):461-70. Minerva Chir. 2004. PMID: 15494673 Review.
• [Chemotherapy for the patients with esophageal cancer].

  Ando N, Shih CH. Ando N, et al. Nihon Geka Gakkai Zasshi. 2002 Apr;103(4):359-63. Nihon Geka Gakkai Zasshi. 2002. PMID: 11993225 Review. Japanese.